David Hallal serves as Chief Executive Officer and Chairman of the Board at Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company focused on developing innovative treatments for neuromuscular and cardiometabolic diseases through precision medicines targeting the TGFβ superfamily. With more than 25 years of experience in the biopharmaceutical and healthcare sectors, Hallal brings a proven track record of leadership in building high-growth companies, advancing clinical pipelines, and executing transformative transactions. Prior to joining Scholar Rock in 2018, Hallal was President and Chief Executive Officer of Cubist Pharmaceuticals from 2011 to 2015, where he led the company's expansion of its anti-infective portfolio, including the successful launch of Zerbaxa (ceftolozane/tazobactam). Under his stewardship, Cubist achieved significant commercial milestones before its acquisition by Merck for $8.4 billion in January 2015. Earlier roles included senior executive positions at Genzyme Corporation, Prudential HealthCare, and J.P. Morgan, where he developed expertise in corporate strategy, business development, and healthcare operations. At Scholar Rock, Hallal has overseen pivotal advancements, including the progression of the company's lead asset, apitegromab—a selective myostatin inhibitor—into Phase 3 clinical trials for spinal muscular atrophy in partnership with Roche/Genentech, as well as expansions into cardiometabolic indications. His visionary leadership has secured substantial financing, forged strategic alliances, and positioned Scholar Rock as a leader in muscle biology therapeutics, consistently delivering on milestones that enhance shareholder value and accelerate patient access to novel therapies.